Similar articles

• Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma.

  Lohmann CP, Kroher G, Bogenrieder T, Spiegel D, Preuner J. Lohmann CP, et al. Lancet. 1999 Apr 17;353(9161):1326. doi: 10.1016/S0140-6736(99)00403-1. Lancet. 1999. PMID: 10218534 No abstract available.
• Rheumatoid arthritis complicating adjuvant interferon-alpha therapy for malignant melanoma.

  Johnson DM, Hayat SQ, Burton GV. Johnson DM, et al. J Rheumatol. 1999 Apr;26(4):1009-10. J Rheumatol. 1999. PMID: 10229440 No abstract available.
• Adjuvant therapy of melanoma: at what cost?

  Spitler LE. Spitler LE. J Clin Oncol. 2001 Feb 15;19(4):1226-8. doi: 10.1200/JCO.2001.19.4.1226. J Clin Oncol. 2001. PMID: 11181688 No abstract available.
• Melanoma: adjuvant therapy and other treatment options.

  Terando A, Sabel MS, Sondak VK. Terando A, et al. Curr Treat Options Oncol. 2003 Jun;4(3):187-99. doi: 10.1007/s11864-003-0020-0. Curr Treat Options Oncol. 2003. PMID: 12718796 Review.
• [Therapy of cutaneous melanoma].

  Dummer R, Nestle FO, Hofbauer G, Böni R, Burg G. Dummer R, et al. Ther Umsch. 1998 Aug;55(8):509-14. Ther Umsch. 1998. PMID: 9757818 Review. German.